HLN.L vs NAGE
HLN.L: A leading global consumer healthcare business managing a portfolio of world-class brands in pain relief, oral health, and wellness. NAGE: Niagen Bioscience is an anti-aging bioscience company advancing NAD+ science through its proprietary Niagen ingredient used in supplements, compounded medicines, and clinical research.
Side-by-side fundamentals
| Metric | HLN.L | NAGE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | £3.76 | $2.51 | |
| Market cap | $44.3B | $199M | |
| P/E | 20.21 | 13.21 | NAGE lower |
| Net margin | +15.2% | +13.4% | HLN.L higher |
| Gross margin | +64.2% | +64.3% | NAGE higher |
| Operating margin FY2025, SEC XBRL | n/a | +12.6% | |
| ROE | +10.2% | +22.7% | NAGE higher |
| ROA FY2025, SEC XBRL | n/a | +16.3% | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +29.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +21.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | n/a | 1.49 | |
| 1-year return as of 2026-10-20 close | +7.0% | -65.2% | HLN.L higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.